Genzyme Europe BV

Azafaros Secures €132M Series B Financing to Advance Rare Lysosomal Storage Disorder Treatments

9 days ago

• Azafaros has raised €132 million in an oversubscribed Series B financing round led by Jeito Capital and co-led by Forbion Growth to advance two Phase 3 clinical programs for nizubaglustat. • Nizubaglustat, a first-in-class dual-acting drug candidate, will enter Phase 3 trials later this year for Niemann-Pick disease Type C and GM1/GM2 gangliosidoses, rare genetic disorders that cause progressive neurodegeneration. • The drug has received multiple regulatory designations including Orphan Drug Designation in both the US and Europe and Fast Track status in the US, highlighting its potential to address significant unmet needs in these fatal pediatric conditions.